Autoradiography confirms that T807/AV1451 binds tau but not TDP-43. Even so, some say the tracer will benefit from more technical work to ensure it will measure small changes robustly in multicenter settings.
At the HAI conference, scientists reported progress toward differential diagnosis of the bewildering spectrum of frontotemporal dementia and atypical Alzheimer’s variants. In some, hypometabolism overlaps with tau, not amyloid.
Researchers explored how the brain’s immune cells influence disease, and how cells and signals from outside the brain pitch in.
Early data suggest that the T807/AV1451 signal relates to cerebrospinal biomarkers of Alzheimer’s, intensifies by up to 10 percent a year, and might nail diagnoses beyond typical AD.
Data come tumbling in as more people are getting scans with the first widely used tau PET tracer. Scientists at HAI were pleased by how closely degeneration and symptoms match up in Alzheimer’s.
The field of tau PET is growing rapidly as the leading tracer T807/AV1451 is more widely used and new compounds from Japan and Switzerland enter the scene with clinical trials of their own.
Tiny spheres full of oxygen soothe neuroinflammation and fight neurodegeneration, researchers reported at SfN. The concept may seem strange, but AD trials are on the horizon.
In mouse models of AD, one astrocyte purinergic receptor makes glia hyperactive, while another may suppress memory. Both are upregulated in the AD brain, researchers report.
Researchers at CTAD added to growing evidence that brain amyloid accumulation presages cognitive decline, although several different factors influence how fast that decline will happen in a given person.
At CTAD 2014, potential drugs for agitation, aggression, and other psychiatric symptoms of Alzheimer’s disease emerged as a prominent theme.
Scientists are finding how calcium dysregulation in mouse models of Alzheimer’s shrivels synapses and impairs neural plasticity, with effects that extend to the network level.
Speakers at CTAD presented new treatment approaches, including a combination of two repurposed drugs that have no activity by themselves.
Small molecules headed for clinical trials target the cell surface protein, displace bound Aβ, and rescue memory in animal models of Alzheimer's.
New therapeutics such as plant-based estrogens and neurosteroids caught notice at CTAD as an approach to try to prevent cognitive decline in women who metabolic markers indicate may be at risk for Alzheimer's.
Internet and tablet-based cognitive tests were trendy at CTAD. If they prove their worth, they may provide a quicker and cheaper way to screen large numbers of people for trials, and track cognitive decline more accurately.